Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A

Open source

DOI: 10.1002/ijc.70397
Published: 2026 Jul 1
Container: International journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ijc.70397,
  title = {Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.},
  author = {Fasching PA and Brucker C and Decker T and Engel A and Göhler T and Jackisch C and Janssen J and Köhler A and Lüdtke-Heckenkamp K and Lüftner D and Marmé F and van Mackelenbergh M and Rautenberg B and Schmidt M and Weide R and Wimberger P and Kisseleff E and Pfister C and Quiering C and Roos C and Wöckel A},
  year = {2026},
  journal = {International journal of cancer},
  doi = {10.1002/ijc.70397},
  url = {https://doi.org/10.1002/ijc.70397}
}

RIS

TY  - JOUR
TI  - Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.
AU  - Fasching PA
AU  - Brucker C
AU  - Decker T
AU  - Engel A
AU  - Göhler T
AU  - Jackisch C
AU  - Janssen J
AU  - Köhler A
AU  - Lüdtke-Heckenkamp K
AU  - Lüftner D
AU  - Marmé F
AU  - van Mackelenbergh M
AU  - Rautenberg B
AU  - Schmidt M
AU  - Weide R
AU  - Wimberger P
AU  - Kisseleff E
AU  - Pfister C
AU  - Quiering C
AU  - Roos C
AU  - Wöckel A
PY  - 2026
JO  - International journal of cancer
DO  - 10.1002/ijc.70397
UR  - https://doi.org/10.1002/ijc.70397
ER  -

APA

PA, F., C, B., T, D., A, E., T, G., C, J., J, J., A, K., K, L., D, L., F, M., M, V. M., B, R., M, S., R, W., P, W., E, K., C, P., C, Q., C, R., & A, W. (2026). Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.. International journal of cancer. https://doi.org/10.1002/ijc.70397

Source records

pubmed · retrieved 2026-09-26T18:33:31.081Z